64 results about "Propionine" patented technology

The present invention relates to the manufacture of the compounds of formula (I)

said compounds of formula (I) being valuable intermediates in the manufacture of Dolastatin 10 analogues, which are useful in the treatment of cancer.

A method of repelling wasps, which method comprises using a preparation comprising (a) one or more of ethyl 3-(N-n-butyl-N-acetylamino)propionate, dihydronepetalactone, and extract of catmint, and (b) at least one compound selected from certain perfume ingredients. This abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.

The invention provides a novel 2-(2-fluorine-4biphenyl)-propionic acid pharmaceutical composition. Flurbiprofen and basic amino acid arginine or lysine form a pharmaceutical composition solution. The composition can be administrated in an injection or oral administration manner and can also be further administrated in a freeze-drying manner. Compared with a flurbiprofen axetil injection, a flurbiprofen composition not only does not influence the antipyretic, anti-inflammation and analgestic effects of the flurbiprofen, but also has the advantages of simple technology, low cost, high quality, stable long shelf life and convenience in quality control, storage and transportation; moreover, compared with a conventional oral preparation, the flurbiprofen composition has the same low gastrointestinal tract adverse reaction as the flurbiprofen axetil injection.

The invention concerns an in vitro method for determining if an individual is infected by a bacterium of the Propionibacterium genus comprising: (i) detecting antibodies directed against at least one protein of sequence SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8, in a biological sample of the individual, and (ii) deducing therefrom that the individual is infected by a bacterium of the Propionibacterium genus. The invention further concerns the kit for diagnosing of such an infection.

The present invention relates to compounds of formula I that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.

The invention discloses an improved production technology of a clobetasol propionate intermediate (betamethasone-17-propionate). Two steps namely cyclo-esterification and hydrolysis in the conventional technology are merged into one step. By merging the steps, the procedure and production period are shortened, the product purity and yield are increased, the energy consumption is reduced, the raw materials and auxiliary materials are saved; the environment pollution is reduced, and the production cost is reduced.

The invention relates to a system for preparing propionate through ethylene carbonylation. The system comprises a separating and refining unit and a bubbling reactor (R1) coupled with the separating and refining unit, a gas-phase reaction raw material (G1) and a liquid-phase reaction raw material (L1) for preparing the propionate product (L6) are subjected to a carbonylation reaction in a bubbling reactor (R1), and a generated propionate-containing material (L2) is separated and purified by a separating and refining unit to prepare the propionate product (L6). Compared with the prior art, through the bubbling reactor, gas-liquid two-phase contact is more sufficient, the gas-liquid two-phase reaction rate is increased, and the raw material conversion rate is increased; the content of the deactivated catalyst in the material returned to the reactor is reduced through the membrane-based solid-liquid separator, the enrichment and regeneration of the deactivated catalyst can be realized, and the utilization rate of the catalyst is also improved.

The invention discloses two methods of preparing a dabigatran etexilate intermediate 3-[N-(2-pyridyl)-3-amino-4-methylamino benzamido]-ethyl propionate (I).

The present invention relates to an improved process for the preparation of substituted Fluticasone derivatives. The invention also reveals the processes for the purification of Fluticasones and related intermediates to provide the highly pure product.

The invention discloses medical application of gigantol and a drug for resisting propionibacterium acnes. The gigantol is applied to preparation of the drug for resisting the propionibacterium acnes,has no toxic and side effects to human bodies, can be used as the drug for resisting the propionibacterium acnes to replace conventional antibiotic drugs which cause relapse and infections easily andis prone to produce drug resistance in some aspects and becomes the first choice clinically, and has great application prospects.

The present invention discloses an application of sophorolipid in preparation of a medicine for preventing against propionibacterium acnes and a biofilm thereof. The sophorolipid is prepared from Wickerhamiella domercqiae var. sophorollipid CGMCC No.1576 through a fermentation method; a concentration of the sophorolipid in effectively inhibiting propionibacterium acnes is 0.12-1.5 g/L and a concentration of the sophorolipid in effectively inhibiting propionibacterium acnes biofilm is 2.0-2.5 g/L. Experiments confirm that the sophorolipid has a significant bacteriostatic effect, does not have any toxic and side effects on human body, can be used to replace a conventional antibiotic medicine that is prone to enable people to relapse and infect and have drug resistance after therapy in certain aspects, and has great application prospects.

The invention discloses a 2-(3-isoquinolinyl)-ethyl propionate derivative and a synthesis method thereof. According to the invention, O-acetyloxime with characteristics of easy preparation, structuraldiversity and multiple reaction centers is used as a raw material, the ortho-position C-H bond of the aromatic ring in the O-acetyloxime is activated under the action of a rhodium salt, a coupling reaction with allenoate is carried out, a series of 2-(3-isoquinolinyl)-ethyl propionate derivatives with different structures are synthesized, and the product can be further converted into a functionalproduct.; and the method has the advantages of easily available raw materials, simple operation, mild reaction conditions, diverse functional groups, and no need of pre-functionalization.

The invention provides a method for detecting beclomethasone propionate related substances. The method optimizes the separation degree of an impurity D and a main peak of beclomethasone propionate through liquid chromatography, and detects the main metabolite (impurity H), and is beneficial to the quality control of beclomethasone propionate and the improvement of dosing accuracy.

The invention provides application of imidazole propionic acid as a biomarker in preparation of a kit for predicting diabetic nephropathy and a related detection kit. The biomarker can be effectively used as an early diagnosis marker for predicting diabetic nephropathy, and has the advantages of accuracy, early stage and high precision.

The invention discloses a method for preparing an (R)-2, 3-diaryl substituted methyl propionate compound, the (R)-2, 3-diaryl substituted methyl propionate compound is synthesized in one step by utilizing a cheap copper catalyst and the catalytic action of a P, N-type chiral ligand, the raw materials are easy to obtain, the preparation method is simple, and the yield and enantioselectivity are good; meanwhile, the catalyst dosage is small, and the cost can be greatly reduced. The method can be used for synthesizing a key intermediate of the medicine tolterodine for treating overactive bladder.

Ethyl 3-(N-(2-(4-(hexyloxycarbonylamidino)phenyl aminomethyl)-1-methyl-1H-benzimidazole-5-carbonyl)-N-(2-pyridyl)amino )propionate methanesulfonate polymorph I (Ia), polymorph II (Ib) and hemihydrate (Ic), with melting points of 180 plus or minus 3 deg. C, 190 plus or minus 3 deg. C and 120 plus or minus 5 deg. C respectively, are new. - Independent claims are also included for the preparation of (Ia)-(Ic). - ACTIVITY - Anticoagulant; Cerebroprotective; Vasotropic. - No biological data is given. - MECHANISM OF ACTION - Thrombin inhibitor.